Data from multiple sources - Curated by Toby Galbraith - Last updated 13 April 2017

Latest news articles

Added 5 days ago Drug news

Phase III study of KRN 23 (burosumab) in X-linked hypophosphatemia meets primary endpoint- Ultragenyx Pharmaceutical/ Kyowa Hakko Kirin

Ultragenyx Pharmaceutical, Kyowa Hakko Kirin Co and Kyowa Kirin International announced positive 24-week data from the randomised, double-blind, placebo-controlled Phase...

Added 13 days ago Drug news

Demcizumab in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin bound) + gemcitabine fails Phase II trial for metastatic pancreatic cancer.- OncoMed Pharma

OncoMed Pharmaceuticals, Inc. reported top-line results from the company's Phase II YOSEMITE clinical trial of demcizumab (anti-DLL4, OMP-21M18) in combination...

Added 15 days ago Drug news

FDA issues Complete Response Letter for supplemental applications for Januvia (sitagliptin) and its combinations for treatment of type 2 diabetes. - Merck Inc.

Merck announced that the FDA has issued a Complete Response Letter regarding Merck’s Supplemental New Drug Applications for Januvia (sitagliptin),...

View all news articles

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis

 

Guidelines

American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis.

The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees.

Added February 2017 ago

Psoriasis overview NICE Pathways

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.

Added February 2017 ago

2016 ESC/EAS guidelines for the management of dyslipidaemias

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient.

Added February 2017 ago

View all guidelines

Journal articles

Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.

Introduction: As type 2 diabetes mellitus (T2DM) advances, patients receiving basal insulin will eventually require another agent on top of their current regimen in order to achieve glycemic control.

Added April 2017 ago

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Objective: To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components...

Added April 2017 ago

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.

Objective: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar ...

Added April 2017 ago

View all journal articles

Clinical trials

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added March 2017 ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added February 2017 ago

View all clinical trials

Blog Posts

Robin Hewings

Diabetes Patients Must Be Better Educated About Their Condition

Posted 1 year ago

Not everyone is convinced that education courses help people look after their diabetes. And the GP I was chatting to a couple of months ago was one of them. He wasn’t sure they worked. People didn’t seem that interested and he wasn’t really sure what people would learn anyway.

Hugh Harvey

Metrics Madness

Posted 1 year ago

You shouldn't judge a book by its cover. That much is true, but it's also common sense not to judge a book by measuring the whiteness of its pages, or the amount of hamsters you can place on it. So why do we measure the fabulous NHS with nonsense metrics?

Joyce Lee

Healthcare Provider: Think Like a Designer!

Posted 1 year ago

Joyce Lee puts forward the case for healthcare providers using goal-directed design. Should we treat patients in order to facilitate their personal treatment goals rather than aiming to simply reduce their symptoms? Do statistical and scientific methodologies neglect the psychosocial emotional management of patients?

CME

Obesity: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0

Testosterone treatment, consultation length and IUD fitting: journals update March 2017

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Ascites: an unusual case: in association with Gut

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
60
View all CME